NO20042364L - Formulering av aminosyrer og riboflavin nyttig for a redusere toksiske effekter av cytotoksisk kjemoterapi - Google Patents

Formulering av aminosyrer og riboflavin nyttig for a redusere toksiske effekter av cytotoksisk kjemoterapi

Info

Publication number
NO20042364L
NO20042364L NO20042364A NO20042364A NO20042364L NO 20042364 L NO20042364 L NO 20042364L NO 20042364 A NO20042364 A NO 20042364A NO 20042364 A NO20042364 A NO 20042364A NO 20042364 L NO20042364 L NO 20042364L
Authority
NO
Norway
Prior art keywords
amino acids
formulation
toxic effects
pharmaceutical compositions
cancer
Prior art date
Application number
NO20042364A
Other languages
English (en)
Other versions
NO332858B1 (no
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Publication of NO20042364L publication Critical patent/NO20042364L/no
Publication of NO332858B1 publication Critical patent/NO332858B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20042364A 2001-11-27 2004-06-07 Anvendelse av en blanding omfattende aminosyrer og riboflavin for fremstilling av en farmasoytisk blanding for a redusere toksiske, ernaeringsmessige og metabolske forstyrrelser assosiert med cancer og cancerkjemoterapi, samt farmasoytisk blanding NO332858B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/995,010 US20030105104A1 (en) 2001-11-27 2001-11-27 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
PCT/US2002/037354 WO2003045372A1 (en) 2001-11-27 2002-11-21 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy

Publications (2)

Publication Number Publication Date
NO20042364L true NO20042364L (no) 2004-06-07
NO332858B1 NO332858B1 (no) 2013-01-21

Family

ID=25541300

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042364A NO332858B1 (no) 2001-11-27 2004-06-07 Anvendelse av en blanding omfattende aminosyrer og riboflavin for fremstilling av en farmasoytisk blanding for a redusere toksiske, ernaeringsmessige og metabolske forstyrrelser assosiert med cancer og cancerkjemoterapi, samt farmasoytisk blanding

Country Status (21)

Country Link
US (2) US20030105104A1 (no)
EP (1) EP1450781B1 (no)
JP (1) JP4614660B2 (no)
KR (1) KR100953483B1 (no)
CN (1) CN100358527C (no)
AT (1) ATE330595T1 (no)
BR (1) BR0214430A (no)
CA (1) CA2468133C (no)
DE (1) DE60212693T2 (no)
EA (1) EA009516B1 (no)
HU (1) HU230986B1 (no)
IL (2) IL162141A0 (no)
MX (1) MXPA04004994A (no)
NO (1) NO332858B1 (no)
NZ (1) NZ532833A (no)
PL (1) PL353656A1 (no)
RO (1) RO121173B1 (no)
SI (1) SI21542A (no)
UA (1) UA78977C2 (no)
WO (1) WO2003045372A1 (no)
ZA (1) ZA200404115B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293335A1 (en) * 2002-08-02 2006-12-28 Qishou Xu Riboflavin derivative and its manufacture and uses
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US20070248693A1 (en) * 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
EP2319581B1 (en) * 2004-11-26 2015-02-25 UCL Business PLC Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
CN101288013B (zh) * 2005-09-19 2010-12-08 Cdm光学有限公司 基于任务的成像系统
MY163134A (en) * 2006-03-15 2017-08-15 Suntory Holdings Ltd Composition containing riboflavin and sesamin-class compounds
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents
JPWO2008105384A1 (ja) * 2007-02-26 2010-06-03 協和発酵バイオ株式会社 シトルリン含有錠剤
SG179481A1 (en) 2007-03-15 2012-04-27 Suntory Holdings Ltd Anti-fatigue agent
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
AU2009293475A1 (en) 2008-09-19 2010-03-25 Nestec S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
AU2014200578B2 (en) * 2008-09-19 2016-08-11 Société des Produits Nestlé S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
KR20220067001A (ko) 2009-04-03 2022-05-24 오세라 테라퓨틱스, 아이엔씨. Ｌ-오르니틴 페닐 아세테이트, 및 이의 제조방법
ES2728948T3 (es) 2009-06-08 2019-10-29 Ucl Business Plc Tratamiento de la inflamación cerebral usando Fenilacetato de L-Ornitina
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
EP2397458A1 (en) * 2010-06-21 2011-12-21 Lunamed AG Organic salts and co-crystals of phenylbutyric acid
CN103327986B (zh) * 2010-07-22 2018-05-25 雷文制药有限公司 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法
NZ607189A (en) * 2010-09-24 2015-04-24 Univ Florida Materials and methods for improving gastrointestinal function
ES2720148T3 (es) 2010-10-06 2019-07-18 Ocera Therapeutics Inc Métodos de fabricación de fenilacetato de L-ornitina
WO2012079058A2 (en) 2010-12-10 2012-06-14 Broady Health Sciences, Llc Use of jasmonate to treat bladder dysfunction
TWI551288B (zh) * 2011-02-17 2016-10-01 Ea Pharma Co Ltd Antimicrobial activity enhancer for chemotherapeutic agents
US20130011488A1 (en) * 2011-07-07 2013-01-10 Nezami Md Mohammad Systems, Methods, and Formulations for Treating Cancer
US10350185B2 (en) 2013-03-11 2019-07-16 University Of Florida Research Foundation, Incorporated Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
WO2015067759A1 (en) * 2013-11-08 2015-05-14 Legacy Healthcare Ltd Method for the management of cancer and treatment of cancer comorbidities
JP6598425B2 (ja) * 2014-02-27 2019-10-30 花王株式会社 疲労の評価方法
AU2015353703B2 (en) 2014-11-24 2021-04-01 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CN105495582A (zh) * 2015-12-11 2016-04-20 北京康比特体育科技股份有限公司 一款抗疲劳、促恢复的保健食品氨基酸组合物
JP7126520B2 (ja) 2017-05-11 2022-08-26 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンフェニルアセテートを製造する方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
JPS58126767A (ja) * 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
DE3672950D1 (de) * 1985-10-23 1990-08-30 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
US5045468A (en) * 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
ATE113441T1 (de) * 1989-10-02 1994-11-15 Sandoz Nutrition Ltd Proteinhydrolysaten.
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
AU679020B2 (en) * 1992-12-23 1997-06-19 Abbott Laboratories Medical foods for the nutritional support of infant/toddler metabolic diseases
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
FR2705765B1 (fr) * 1993-04-29 1995-08-18 Eurofours Sa Porte de four.
NZ248605A (en) * 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
US5547927A (en) * 1993-05-28 1996-08-20 Abbott Laboratories Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
US5776913A (en) * 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
CA2254772C (en) * 1996-05-14 2004-01-27 Stanislaw R. Burzynski Liposomal antineoplaston therapies with markedly improved antineoplastic activity
US5817927A (en) * 1997-04-11 1998-10-06 Betzdearborn Inc. Method and apparatus for monitoring water process equipment
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
ES2205646T3 (es) 1999-06-26 2004-05-01 B. Braun Melsungen Ag Solucion acuosa para la nutricion parenteral.
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US6377094B1 (en) * 2002-03-25 2002-04-23 Oak Technology, Inc. Arbitrary waveform synthesizer using a free-running ring oscillator

Also Published As

Publication number Publication date
JP2005518361A (ja) 2005-06-23
DE60212693D1 (de) 2006-08-03
JP4614660B2 (ja) 2011-01-19
NO332858B1 (no) 2013-01-21
IL162141A (en) 2009-05-04
US7427619B2 (en) 2008-09-23
CN1596109A (zh) 2005-03-16
CA2468133A1 (en) 2003-06-05
US20030105104A1 (en) 2003-06-05
HUP0402240A3 (en) 2012-09-28
NZ532833A (en) 2006-12-22
EA200400737A1 (ru) 2004-12-30
KR100953483B1 (ko) 2010-04-16
AU2002352843A1 (en) 2003-06-10
IL162141A0 (en) 2005-11-20
SI21542A (sl) 2005-02-28
HU230986B1 (hu) 2019-08-28
KR20040065565A (ko) 2004-07-22
MXPA04004994A (es) 2005-04-08
ATE330595T1 (de) 2006-07-15
RO121173B1 (ro) 2007-01-30
DE60212693T2 (de) 2007-07-05
HUP0402240A2 (hu) 2005-02-28
CA2468133C (en) 2011-02-22
EP1450781A1 (en) 2004-09-01
BR0214430A (pt) 2004-11-03
ZA200404115B (en) 2005-11-30
CN100358527C (zh) 2008-01-02
EP1450781B1 (en) 2006-06-21
EA009516B1 (ru) 2008-02-28
US20050182064A1 (en) 2005-08-18
UA78977C2 (en) 2007-05-10
PL353656A1 (en) 2003-06-02
WO2003045372A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
NO20042364L (no) Formulering av aminosyrer og riboflavin nyttig for a redusere toksiske effekter av cytotoksisk kjemoterapi
PL365783A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
NO991836D0 (no) Antranilinsyrederivater som modulatorer av multimedikamentresistens
LU92323I2 (fr) La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate
YU58103A (sh) Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona
WO2001027109A3 (de) Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate
WO2002043765A3 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
TNSN07238A1 (en) Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes. pharmaceutical formulations containing the same, and use thereof as medicaments
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
CA2514224A1 (en) Liquid pharmaceutical formulations of palonosetron
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
MXPA06000418A (es) Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral.
ATE521624T1 (de) Peptide und medizinische zusammensetzungen mit denselben
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
DE602005014087D1 (de) 7h-pyrrolopyrimidinderivate
AU2003218141A1 (en) Potent, simplified derivatives of immunosuppressive agents
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
HUP0402062A2 (hu) Alkanoil-L-karnitin alkalmazása merevedési zavar kezelésére és ezt tartalmazó gyógyszerkészítmények
RS20060435A (en) Compostions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug
UY27628A1 (es) "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco"
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
ECSP055804A (es) Composición farmacéutica
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees